After investing in their Series B, Lilly bags a license for a batch of metabolic candidates

Eli Lilly will license in Regor Therapeutics therapies for metabolic disorders, as a part of an agreement announced Friday that will give the Chinese biotech an upfront payment of up to $50 million, part of which is an equity investment.

In a vaguely worded release, Lilly...

Click to view original post